STOCK FUTURES CLIMB AS RALLY LOOKS SET TO CONTINUE

Equities rallied at end of last week, getting a boost from a "Goldilocks" U.S. jobs print

Bicycle Therapeutics PLC (50BA.MU)

Munich - Munich Delayed Price. Currency in EUR

Add to watchlist

22.20

0.00

(0.00%)

As of 08:11AM CEST. Market open.

Loading interactive chart...

Simply Wall St.
Bicycle Therapeutics First Quarter 2024 Earnings: Beats Expectations
Bicycle Therapeutics ( NASDAQ:BCYC ) First Quarter 2024 Results Key Financial Results Revenue: US$19.5m (up 299% from...
GuruFocus.com
Bicycle Therapeutics PLC (BCYC) Q1 2024 Earnings: Narrowing Losses Amidst Robust R&D Progress
Comparison with Analyst Estimates and Strategic Developments
Business Wire
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
CAMBRIDGE, England & BOSTON, May 02, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the first quarter ended March 31, 2024.